|
Most prominent in this group at the moment are Eli Lilly’s (LLY) donanemab and Alzheon’s ALZ-801 |
|---|
In the wake of the FDA’s approval of Biogen’s (BIIB) and Eisai’s (OTCPK:ESALY) drug Aduhelm for Alzheimer’s disease, several other companies are posed to have their anti-amyloid drugs approved by the FDA as well. Most prominent in this group at the moment are Eli Lilly’s (LLY) donanemab and Alzheon’s ALZ-801, along with Biogen and Eisai’s lecanemab. ALZ-801 has the advantage over the other three drugs of being taken orally rather than requiring intravenous infusions. ALZ-801 has another advantage in that it does not cause serious side effects such as bleeding in the brain and brain swelling.